Edwards Lifesciences is trading roughly flat as the stock consolidates ahead of its November 4, 2026, third-quarter earnings report, where analysts anticipate $0.73 in diluted EPS and continued double-digit growth. While institutional interest remains positive, evidenced by Sivik Global Healthcare LLC boosting its stake by 125% during the third quarter, the broader healthcare sector has seen mixed reactions to recent earnings reports. Despite the stock currently sitting below its 50-day moving average by 2.7%, market sentiment remains supported by an average analyst price target of $102.87.